<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report on a patient with Fanconi's <z:hpo ids='HP_0001903'>anemia</z:hpo> (FA) who developed a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) with complex karyotypic abnormalities (trp 1q23q42, <z:mp ids='MP_0004026'>monosomy</z:mp> 20, <z:mp ids='MP_0004027'>trisomy</z:mp> 13) at the age of 28 </plain></SENT>
<SENT sid="1" pm="."><plain>The patient achieved a complete hematological and cytogenetic remission after treatment with sequential high-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi>/<z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> followed by G-CSF (5 micrograms/kg) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0005528'>Bone marrow hypoplasia</z:hpo> was prolonged with 38 days of <z:hpo ids='HP_0001913'>granulocytopenia</z:hpo> &lt; 500/microliters and 62 days of platelet transfusion dependency </plain></SENT>
<SENT sid="3" pm="."><plain>Nonhematological toxicity did not exceed that of patients without underlying FA </plain></SENT>
<SENT sid="4" pm="."><plain>Remission duration was 7 months </plain></SENT>
<SENT sid="5" pm="."><plain>This observation shows the feasibility of high-dose Ara C treatment in patients with FA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Although hematopoiesis remained clonal in remission, the suppression of the cytogenetically abnormal clones transiently reversed the antecedent long-lasting <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> </plain></SENT>
</text></document>